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Abstract 
Background 
In calculations of burden of disease using disability-adjusted life years, disability weights are 
needed to quantify health losses relating to non-fatal outcomes, expressed as years lived with 
disability. In 2012 a new set of global disability weights was published for the Global Burden 
of Disease 2010 (GBD 2010) study. That study suggested that comparative assessments of 
different health outcomes are broadly similar across settings, but the significance of this 
conclusion has been debated. The aim of the present study was to estimate disability weights 
for Europe for a set of 255 health states, including 43 new health states, by replicating the 
GBD 2010 Disability Weights Measurement study among representative population samples 
from four European countries. 
Methods 
For the assessment of disability weights for Europe we applied the GBD 2010 disability 
weights measurement approach in web-based sample surveys in Hungary, Italy, Netherlands, 
and Sweden. The survey included paired comparisons (PC) and population health 
equivalence questions (PHE) formulated as discrete choices. Probit regression analysis was 
used to estimate cardinal values from PC responses. To locate results onto the 0-to-1 
disability weight scale, we assessed the feasibility of using the GBD 2010 scaling approach 
based on PHE questions, as well as an alternative approach using non-parametric regression. 
Results 
In total, 30,660 respondents participated in the survey. Comparison of the probit regression 
results from the PC responses for each country indicated high linear correlations between 
countries. The PHE data had high levels of measurement error in these general population 
samples, which compromises the ability to infer ratio-scaled values from discrete choice 
responses. Using the non-parametric regression approach as an alternative rescaling 
procedure, the set of disability weights were bounded by distance vision mild impairment and 
anemia with the lowest weight (0.004) and severe multiple sclerosis with the highest weight 
(0.677). 
Conclusions 
PC assessments of health outcomes in this study resulted in estimates that were highly 
correlated across four European countries. Assessment of the feasibility of rescaling based on 
a discrete choice formulation of the PHE question indicated that this approach may not be 
suitable for use in a web-based survey of the general population. 
Keywords 
Value of life, Disability weight, Disease burden, Disability adjusted life years, Summary 
measure of population health, Prioritisation 
Background 
Priority-setting for health care policies and research is informed increasingly by burden of 
disease and injury studies, because these studies provide knowledge on the size of health 
problems and the potential benefit of proposed interventions and policies directed against 
these problems [1,2]. Burden of disease can be expressed in disability-adjusted life years 
(DALYs), a summary measure of population health that captures health losses associated 
with mortality and with different non-fatal outcomes of diseases and injuries in a single figure 
[3-5]. The DALY methodology was developed in the 1990s for the Global Burden of Disease 
(GBD) study [6-10] and has since been used in many other disease burden studies (e.g. [11-
16]) as well as in cost-utility studies (e.g.[17-19]). 
DALYs are calculated by adding years of life lost (YLLs) and years lived with disability 
(YLDs). YLLs represent the life years lost due to premature death and are calculated for any 
cause by multiplying the number of deaths by a standardized expectation of remaining life 
years at the age of death. YLDs represent the life years lost due to disability, adjusted for the 
severity of the disability. YLDs are computed for a given health outcome by multiplying the 
prevalence of that outcome by a disability weight that has a value between 0 (equivalent to 
full health) and 1 (equivalent to death). 
For the 1996 revision of the GBD a large set of global disability weights was derived in a 
group exercise in which a panel of health experts assessed conditions using a range of 
techniques, and the scale was determined largely by responses to two different variants of a 
measurement method called the person trade-off [3,20]. This approach has been criticized, 
particularly regarding aspects such as the health construct, measurement techniques, and 
panel composition [21-23]. Because of a need to improve the approach and a need for 
disability weights that reflect the views of the global population, a new approach to 
measuring disability weights was developed for the GBD 2010 study [24,25]. This study used 
a conceptually less difficult measurement technique to elicit health state valuations (paired 
comparisons instead of the person trade-off). Health state descriptions focused primarily on 
the impact of a condition on functional health status. The study collected responses from 
30,230 people in 167 countries. For five countries (Bangladesh, Indonesia, Peru, Tanzania, 
and the United States of America) household sample surveys were used, with samples 
designed to be representative of the population in a particular geographical area (or in the 
case of the USA, nationally representative). An important finding of the GBD 2010 disability 
weights study was that comparative assessments of different disabling sequelae, as revealed 
in paired comparisons, are similar in samples that vary with respect to cultural, educational, 
environmental, and demographic circumstances [25]. The GBD 2010 disability weights study 
has been criticized regarding the estimated weights for certain conditions, such as vision loss, 
and for the interpretation of evidence on the level of international agreement in paired 
comparison responses [26,27]. 
For some purposes in which the need for standardization and global comparison is not 
primary, it is useful to have disability weights that reflect the particular views of a specific 
population under study, for example in a national burden of disease study [28]. The present 
study was initiated as part of a study on the burden of communicable diseases in the 
European Union/ European Economic Area (EEA)/ European Free Trade Association 
(EFTA) countries [29,30], which motivates an interest in disability weights from European 
population samples. The GBD 2010 disability weights study did include respondents from 
European countries; however, these respondents were not representative for these European 
countries, as they participated in an open access web-based survey rather than in nationally 
representative sample surveys. This raises a question as to whether the current GBD 2010 
disability weights are suitable for national burden of disease studies in European countries. 
The objectives of the present study were to: 
1) 
Assess the feasibility of replicating the GBD 2010 disability weights measurement study 
in a set of four nationally representative sample surveys in European countries using web-
based surveys 
2) Estimate disability weights for Europe for a set of 255 health states, including 43 new health states 
3) Evaluate consistency in comparative assessments of disability across selected European countries. 
Materials and methods 
Study design 
For the assessment of a set of disability weights for Europe we replicated the online survey 
protocol used in the GBD 2010 disability weights measurement study [25]. 
Health states and description 
In total 255 health states were evaluated. These health states can be subdivided into four 
categories: original GBD 2010 health states (n = 172) [25], new health states (n = 43), 
modified GBD 2010 health states (n = 33), and health states that were included for 
experimental purposes but were not part of the European disability weights study (n = 7). 
Regarding the original GBD 2010 health states, we selected all health states associated with 
infectious diseases, injuries, and vision and hearing loss—of primary interest for the new 
European study on communicable disease—and supplemented these health states with a 
further subset of GBD 2010 health states selected to have some representation from each of 
the other health state categories (e.g., cancer, cardiovascular and circulatory disease, diabetes, 
digestive and genitourinary disease, chronic respiratory disease, musculoskeletal disorders, 
neurological disorders, and other). 
For the 43 new health states lay descriptions were constructed following the same general 
design principles used in GBD 2010. The descriptions have a word limit of 70 words or less 
and were constructed through an iterative process. The brief lay descriptions are intended to 
highlight the major functional consequences and symptoms associated with the health state 
using simple, non-clinical vocabulary. Disease experts and health professionals were 
consulted to ensure that the descriptions were appropriate and reflective of the common 
manifestations of the disabling sequela in question. 
For the 33 modified health states the description of the health states of original GBD health 
states were amended because they were found to be lacking in consistency or in content 
[25,26]. For instance, in the case of spinal cord injury, incontinence was added to the 
description. Both the original and modified health state descriptions were evaluated in this 
study in order to facilitate direct comparison. The health state descriptions that were 
evaluated in this study are included in Additional file 1. 
Health state valuation 
To elicit health state valuations for the 255 health states, two valuation techniques were used: 
paired comparison (PC) and population health equivalence (PHE). All of the 255 health states 
were evaluated with the PC technique, and a subset of 28 states were evaluated with PHE 
questions. Paired (sometimes called “pairwise”) comparison is an ordinal measurement 
method. With this method, persons in two alternative health states are presented, and 
respondents have to decide whom they regard as being healthier. PHE questions ask for a 
retrospective assessment that compares two hypothetical health programs. The first health 
program prevented 1,000 people from getting an illness that causes rapid death; the second 
health program prevented 1,500, 2,000, 3,000, 5,000, or 10,000 (dependent on the bid that 
was selected randomly for each question) people from getting an illness that is not fatal but 
causes the lifelong health problems of one of the selected health states. The respondents are 
asked to choose which health program they think produced the greater overall population 
health benefit. 
The 28 health states that were evaluated here were a subset of the 30 health states evaluated 
with the PHE in the GBD 2010 disability weights study. 
Panel participants 
The panel consisted of members of the general public aged 18 to 65 years from four 
European countries, namely Hungary, Italy, the Netherlands, and Sweden. We selected these 
four countries because they are believed to be representative of four regions of Europe 
(Eastern, Southern, Central, and Northern Europe) with regards to age, sex, and educational 
level. We used existing large internet panels in the selected European countries. By selecting 
panel members with certain characteristics (in our case: age, sex, and educational level) from 
the existing large panels, the panel of participants for this study could be composed in such a 
way that the respondents were representative of the population aged 18 to 65 in the selected 
countries. The procedure to invite panelists to fill in the questionnaire differed between the 
Netherlands and the other three countries. In the Netherlands panelists were invited via 
individual emails. In the three other countries a link to the questionnaire was placed on a 
website. Subsequently, the relevant respondents were selected based on their characteristics 
as assessed in the questionnaire. Because of this, the specific number of panelists that were 
invited to fill in the questionnaire in Hungary, Italy, and Sweden is not known, and the 
response rate could not be calculated for these countries. 
Data collection 
The GBD 2010 disability weights study consisted of two main components: a) a face-to-face 
or telephone survey based on a subset of the sequelae (household survey) and b) a web-based 
survey based on the full set of sequelae. In the current study we used the GBD 2010 web-
based survey instrument. 
Three versions of the web-based survey were developed. The number and framing of the PC 
questions differed per version. Each version included questions regarding the demographics 
of the respondent (age, sex, educational and income level, and disease experience) and three 
PHE and PC questions. The first version of the questionnaire included 15 PC questions with a 
chronic framing, the second version included 15 PC questions with a temporary framing, and 
the third version included five PC questions with a chronic framing to accommodate PHE 
questions. Chronic framing means that the participants are asked to consider the situation that 
the described health state will last for the rest of a person’s life. Temporary framing means 
that the participant is asked to consider that the health state will last for one week. 
The survey and description of health states were translated from English into Dutch, 
Hungarian, Italian, and Swedish using translation software and subsequently translated back 
into English. The translations were verified independently by bilingual native speakers. 
In the period 23 September to 11 November 2013 the disability weight survey was 
administered via the internet. The survey versions and health states were randomly assigned 
to the respondents following a randomization algorithm. First, the algorithm randomly 
allocated the survey version, based on the lowest percentage of respondents at that moment 
for each version. After the version was allocated, the algorithm selected the health states 
based on the minimum number of allocations that the health state had at that moment, i.e., the 
probability of selection was inversely proportional to number of allocations that health state 
at that moment. 
Data analysis 
Analyses were performed with R (version 3.0.2) [31] and SPSS (version 21). The PC data 
were analyzed through probit regression, following the approach used in GBD 2010 [25]. 
Coefficients from the probit regression were compared across the four European countries in 
order to assess variation in the comparative assessments of different disabilities, as expressed 
in paired comparisons. To examine the feasibility of using the PHE rescaling method from 
the GBD 2010, we evaluated the PHE data in terms of the probabilities of choosing the 
alternative program over the first program by health state and by bid, as well as by 
educational level. This analysis thus focused on “sensitivity to scope” in the PHE [32], i.e., 
the degree to which bid probabilities are dependent on the number of people benefiting from 
the program, as the conceptual model for analyzing PHE data presumes, as well as 
responsiveness to variation in the severity of the different outcomes under consideration, i.e., 
the degree to which bid probabilities are sensitive to the nature of the health outcomes 
affected by the two programs in each comparison. As an alternative rescaling procedure, we 
ran a non-parametric regression model (loess) of the probit regression coefficients against the 
logit-transformed disability weights from GBD 2010. Based on this loess fit, we then 
predicted logit transformed disability weights for each of the probit coefficients, including the 
ones that were not matched to a GBD 2010 health state. Finally, we applied an inverse logit 
transformation at the draw level to these predicted disability weights. Uncertainty intervals 
around the mean disability weights were estimated through a Monte Carlo simulation 
approach. First, 200 samples of the paired comparison coefficients were generated based on 
their probit estimated mean and standard deviation. These samples were then used to produce 
200 loess fits, as described above. Based on each loess fit, 200 samples were generated for 
each of the disability weights, yielding a total of 40,000 samples per disability weight. 
Uncertainty intervals around the mean disability weights were derived as the 2.5th and 97.5th 
percentile of the corresponding distribution of sampled weights. 
Results 
Respondents 
A total of 30,660 respondents filled in the questionnaire. Approximately half of the 
respondents were male. The average age was 42.3 (SD 13.1). 76% of the respondents had a 
low or medium educational level and the majority (84.9%) had a low to medium income 
level. Table 1 shows the characteristics of the respondents. The response rate in the 
Netherlands was 63.1%. The response rates of the other countries could not be calculated. 
  
Table 1 Characteristics of the 30,600 participants 
Sex  
Male 48.0% 
Age (years)  
18-34 31.2% 
35-49 35.1% 
50-65 33.7% 
Educational level  
Low 29.8% 
Medium 45.7% 
High 24.6% 
Income level  
Low 39.5%
Medium 45.4% 
High 15.1% 
Country  
Hungary 19.8% 
Italy 26.3% 
Netherlands 26.2%
Sweden 27.8% 
Paired comparison 
Figure 1 shows a heat map of the paired comparison response probabilities for the 255 × 255 
possible paired comparisons. Each cell in the heat map indicates the response probability for 
one pair of states. The colors of the heat map correspond to the probability that the first health 
state in a pair comparison is chosen as the healthier outcome. Figure 1 shows a relatively 
smooth transition in colors from high to low probabilities between the upper left and lower 
right corner, indicating a small amount of measurement error and high internal consistency. 
Figure 1 Response probabilities for paired comparisons. Red corresponds to probabilities 
that are 0.25 or lower. Blue corresponds to probabilities that are 0.75 or higher. Green, 
yellow, and orange correspond to probabilities between 0.25 and 0.75. A smooth transition in 
colors from high to low probabilities between the upper left and lower right corners indicates 
a small amount of measurement error and high internal consistency, whereas a completely 
random assortment of colors would indicate a high amount of measurement error and low 
internal consistency. It should be noted that not every possible 255 × 255 pair was evaluated 
with the pairwise comparison. This is indicated by the white spaces in the figure. 
Of the respondents, 6.9% were given the same pair in the first and 15th paired comparison 
question, and of these 51% were presented in the same order and 49% in reversed order. This 
deliberate repetition allows assessment of test-retest reliability of PC responses. Overall, the 
probability of choosing the same health state was slightly higher if the two health states were 
presented in the same order (probability of choosing the same health state: 0.75) compared to 
reversed order (probability of choosing the same health state: 0.73). This is above the 
probability of chance agreement (0.50). The probabilities that respondents from Hungary (n = 
414), Italy (n = 564), the Netherlands (n = 553), and Sweden (n = 573) chose the same health 
state in the retest were 0.78, 0.72, 0.73, and 0.75, respectively. 
Comparison of the regression results on the paired comparison responses for each country 
with those run on the pooled data showed high linear correlations in all four cases (Pearson’s 
correlation coefficients between 0.855 and 0.978; p < 0.001; see Table 2). 
Table 2 Pearson’s correlation coefficients for country-specific and pooled probit 
regression analyses of paired comparison responses 
 Hungary Italy Sweden Pooled 
Netherlands 0.867* 0.855* 0.894* 0.941* 
Hungary - 0.944* 0.929* 0.966* 
Italy  - 0.935* 0.967* 
Sweden   - 0.978* 
*correlation is significant at the 0.01 level. 
Population health equivalence 
With the PHE a choice has to be made between two hypothetical health programs. We found 
that the probability of choosing the second health program option was higher as the bid 
increased (i.e., when the number of beneficiaries was greater), as expected. However, the 
span of probabilities between the lowest bid value (with 1,500 beneficiaries) and the highest 
bid value (with 10,000 beneficiaries) was generally lower than expected and varied by 
educational level on the PHE responses. On average, the differences between the probabilities 
of choosing the second health program at the highest versus the lowest bid values were 0.12, 
0.16, and 0.19 for the lower, middle, and higher educational level, respectively. 
The responsiveness to variation in the severity of the different outcomes under consideration 
was also lower than expected. While the 28 health states could be ranked according to the 
probabilities of choosing the second program (which prevented a specified number of cases 
of each outcome), there was relatively little variation across the range of health outcomes 
with quite distinct profiles of severity. 
Figure 2 shows the probabilities of choosing the second program at each bid value for each of 
the 28 health states that were evaluated with the PHE. For comparison, a similar graph of the 
PHE data from the GBD 2010 disability weights measurement study is presented. The graphs 
show that the GBD 2010 PHE data had better discrimination by bid (higher sensitivity to 
scope), illustrated by longer lines between the bids within one health state, as well as a better 
discrimination by health state (better responsiveness to variation in the severity of the 
different outcomes), illustrated by a steeper gradient across health states, moving from left to 
right. These results suggest that the PHE responses in the present study were subject to high 
levels of measurement error; consequently, the feasibility of using discrete choice 
formulation in general population web-based sample surveys may be questioned. 
Figure 2 Probability of choosing the second program at each bid value for each of the 28 
health states that were evaluated with the population health equivalence questions, in 
the present study (top panel) compared to results in the GBD 2010 study (bottom 
panel). Each line represents one health state and each dot represents a bid within one health 
state. 
Disability weights 
Given the evident lack of feasibility of the discrete choice PHE in this sample, a non-
parametric regression approach was used as an alternative rescaling procedure to locate 
results onto the 0-to-1 disability weight scale. The R-squared from that regression was 0.801, 
based on 172 health states that were in both studies. The resulting disability weights and 95% 
uncertainty interval (UI) are shown in Table 3 (original GBD 2010 health states, new health 
states, and modified GBD 2010 health states). Distance vision mild impairment and mild 
anemia shared the lowest disability weight (0.004) and severe multiple sclerosis had the 
highest disability weight (0.677). 
Table 3 Estimated disability weights with uncertainty intervals (UI) 
  Disability weight (+ 
UI) 
Category1  Mean 2.5% 97.5%
 Infectious diseases    
Original Infectious disease, acute episode, mild 0.007 0.005 0.01 
Original Infectious disease, acute episode, moderate 0.051 0.039 0.06 
Original Infectious disease, acute episode, severe 0.125 0.104 0.152 
Original Infectious disease, post-acute consequences (fatigue, emotional lability, insomnia) 0.217 0.179 0.251 
Original Diarrhea, mild 0.073 0.061 0.092 
Original Diarrhea, moderate 0.149 0.12 0.182 
Original Diarrhea, severe 0.239 0.202 0.285 
Original Epididymo-orchitis 0.176 0.143 0.208 
Original HIV cases, symptomatic, pre-AIDS 0.351 0.299 0.394 
Original HIV/AIDS cases, receiving ARV treatment 0.108 0.089 0.132 
Original AIDS cases, not receiving ARV treatment 0.574 0.518 0.635 
Original Ear pain 0.015 0.011 0.019 
Original Tuberculosis, not HIV infected 0.308 0.264 0.353 
Original Tuberculosis, HIV infected 0.383 0.345 0.435 
Original Tuberculosis of vertebrae 0.287 0.245 0.332 
New Subacute sclerosing panencephalitis – phase 1 0.088 0.07 0.108 
New Thrombocytopenic purpura 0.167 0.134 0.201 
New Lymphogranuloma Venereum - local infection 0.070 0.057 0.087 
New Subacute sclerosing panencephalitis – phase 2 0.276 0.235 0.323 
New Subacute sclerosing panencephalitis – phase 3 0.543 0.481 0.606 
 Cancer    
Original Cancer, diagnosis and primary therapy 0.265 0.222 0.303 
Original Cancer, metastatic 0.358 0.317 0.417 
Original Stoma 0.125 0.104 0.155 
Original Terminal phase, with medication (for cancers, end-stage kidney/liver disease) 0.515 0.459 0.572 
Original Terminal phase, without medication (for cancers, end-stage kidney/liver disease) 0.588 0.524 0.65 
 Cardiovascular and circulatory disease    
Original Acute myocardial infarction, days 3-28 0.098 0.08 0.121 
Original Angina pectoris, moderate 0.103 0.089 0.128 
Original Cardiac conduction disorders and cardiac dysrhythmias 0.295 0.258 0.343 
Original Heart failure, mild 0.052 0.041 0.063 
Original Heart failure, moderate 0.070 0.057 0.085 
Original Heart failure, severe 0.173 0.14 0.205 
Original Stroke, long-term consequences, moderate 0.075 0.059 0.093 
Original Stroke, long-term consequences, severe plus cognition problems 0.580 0.519 0.639 
 Diabetes, digestive, and genitourinary disease    
Original Diabetic neuropathy 0.165 0.134 0.199 
Original Chronic kidney disease (stage IV) 0.108 0.09 0.132 
Original End-stage renal disease, on dialysis 0.487 0.432 0.544 
Original End-stage renal disease, with kidney transplant 0.030 0.023 0.037 
Original Decompensated cirrhosis of the liver 0.163 0.136 0.194 
Original Crohn's disease or ulcerative colitis 0.221 0.184 0.26 
Original Infertility, primary 0.008 0.005 0.01 
Original Infertility, secondary 0.007 0.005 0.01 
New Heart burn & reflux “GERD” 0.038 0.029 0.046 
New Constipation 0.075 0.061 0.092 
New Vaginal discharge 0.018 0.013 0.022 
New Dyspareunia 0.022 0.017 0.027 
New Irritable bowel syndrome 0.062 0.05 0.077 
New Stress incontinence 0.032 0.024 0.038 
 Chronic respiratory diseases    
Original Asthma, controlled 0.020 0.015 0.024 
Original Asthma, partially controlled 0.045 0.035 0.055 
Original COPD and other chronic respiratory problems, mild 0.025 0.019 0.031 
Original COPD and other chronic respiratory problems, moderate 0.284 0.242 0.329 
Original COPD and other chronic respiratory problems, severe 0.418 0.367 0.468 
 Mental, behavioural, and substance abuse disorder    
New Harmful alcohol use 0.106 0.087 0.132 
New Alcohol use disorder, very mild 0.154 0.123 0.187 
Original Alcohol use disorder, mild 0.209 0.175 0.247 
Original Alcohol use disorder, moderate 0.357 0.309 0.41 
Original Alcohol use disorder, severe 0.500 0.457 0.567 
New Cannabis dependence, mild 0.043 0.033 0.052 
Original Cannabis dependence 0.191 0.147 0.235 
New Amphetamine dependence, mild 0.088 0.072 0.11 
Original Amphetamine dependence 0.474 0.417 0.531 
New Cocaine dependence, mild 0.131 0.107 0.163 
Original Cocaine dependence 0.493 0.444 0.549 
New Opioid dependence, mild 0.365 0.314 0.417 
Original Heroin and other opioid dependence 0.624 0.553 0.707 
Original Anxiety disorders, mild 0.045 0.035 0.054 
Original Anxiety disorders, moderate 0.119 0.098 0.15 
Original Anxiety disorders, severe 0.422 0.372 0.475 
Modified Major depressive disorder, mild episode 0.129 0.102 0.154 
Original Major depressive disorder, moderate episode 0.294 0.248 0.341 
Original Major depressive disorder, severe episode 0.571 0.509 0.635 
Modified Intellectual disability, borderline 0.014 0.01 0.017 
Modified Intellectual disability, mild 0.053 0.041 0.065 
Modified Intellectual disability, moderate 0.123 0.097 0.152 
Modified Intellectual disability, severe 0.141 0.112 0.174 
Modified Intellectual disability, profound 0.213 0.177 0.255 
New Borderline personality disorder 0.193 0.16 0.228 
New Somatoform disorder 0.144 0.116 0.174 
 Hearing and vision loss    
Modified Hearing loss, mild 0.011 0.007 0.014 
Modified Hearing loss, moderate 0.037 0.028 0.045 
Modified Hearing loss, severe 0.152 0.125 0.187 
Modified Hearing loss, profound 0.235 0.197 0.274 
Modified Hearing loss, mild, with ringing 0.027 0.021 0.034 
Modified Hearing loss, moderate, with ringing 0.070 0.056 0.087 
Modified Hearing loss, severe, with ringing 0.274 0.231 0.318 
Modified Hearing loss, profound, with ringing 0.242 0.204 0.288 
Modified Hearing loss, complete, with ringing 0.313 0.268 0.361 
Original Unilateral hearing loss 0.008 0.005 0.012 
Original Near vision impairment 0.012 0.008 0.015 
Original Distance vision, mild impairment 0.004 0.002 0.005 
Original Distance vision, moderate impairment 0.034 0.027 0.042 
Original Distance vision, severe impairment 0.158 0.13 0.193 
Modified Distance vision blindness 0.173 0.145 0.213 
 Musculoskeletal disorders    
Original Back pain, acute, with leg pain 0.275 0.237 0.324 
Original Back pain, acute, without leg pain 0.298 0.254 0.343 
Original Back pain, chronic, with leg pain 0.395 0.345 0.45 
Original Back pain, chronic, without leg pain 0.365 0.322 0.413 
New Low back pain, mild 0.024 0.018 0.03 
New Low back pain, moderate 0.060 0.05 0.074 
Original Neck pain, acute, mild 0.062 0.05 0.075 
Original Neck pain, acute, severe 0.224 0.19 0.268 
Original Neck pain, chronic, mild 0.111 0.089 0.136 
New Neck pain, moderate 0.056 0.044 0.067 
Original Neck pain, chronic, severe 0.311 0.263 0.359 
Original Musculoskeletal problems, lower limbs, mild 0.027 0.021 0.032 
Original Musculoskeletal problems, lower limbs, moderate 0.094 0.08 0.12 
Original Musculoskeletal problems, lower limbs, severe 0.134 0.11 0.165 
Original Musculoskeletal problems, upper limbs, mild 0.041 0.032 0.05 
Original Musculoskeletal problems, upper limbs, moderate 0.138 0.114 0.167 
Original Musculoskeletal problems, generalized, moderate 0.344 0.3 0.391 
Original Musculoskeletal problems, generalized, severe 0.518 0.457 0.576 
New Osteomyelitis 0.053 0.041 0.065 
New Shoulder lesions 0.016 0.012 0.02 
 Injuries    
Modified Amputation of finger(s), excluding thumb 0.007 0.005 0.009 
Original Amputation of thumb (long term) 0.015 0.011 0.018 
New Amputation of one upper limb (long term, without treatment) 0.105 0.085 0.128 
Modified Amputation of one upper limb (with treatment) 0.048 0.037 0.057 
Modified Amputation of both upper limbs (long term, with treatment) 0.121 0.097 0.153 
Modified Amputation of both upper limbs (long term, without treatment) 0.392 0.344 0.451 
Modified Amputation of one lower limb (long term, with treatment) 0.041 0.031 0.049 
Original Amputation of one lower limb (long term, without treatment) 0.188 0.153 0.225 
Modified Amputation of both lower limbs (long term, with treatment) 0.088 0.071 0.107 
Modified Amputation of both lower limbs (long term, without treatment) 0.427 0.381 0.484 
Original Amputation of toe 0.007 0.005 0.009 
Original Burns, <20% total burned surface area without lower airway burns (short term, with or without treatment) 0.154 0.125 0.189 
Original Burns, <20% total burned surface area or <10% total burned surface area if head/neck or hands/wrist 
involved (long term, with or without treatment) 
0.019 0.014 0.024 
Original Burns, ≥20% total burned surface area (short term, with or without treatment) 0.262 0.218 0.303 
Original Burns, ≥20% total burned surface area or ≥10% total burned surface area if head/neck or hands/wrist 
involved (long term, with treatment) 
0.161 0.131 0.195 
Original Burns, ≥20% total burned surface area or ≥10% total burned surface area if head/neck or hands/wrist 
involved (long term, without treatment) 
0.424 0.372 0.478 
Original Crush injury (short or long term, with or without treatment) 0.138 0.112 0.169 
Original Dislocation of hip (long term, with or without treatment) 0.018 0.014 0.023 
Original Dislocation of knee (long term, with or without treatment) 0.112 0.094 0.141 
Original Dislocation of shoulder (long term, with or without treatment) 0.041 0.033 0.051 
Original Other injuries of muscle and tendon (includes sprains, strains and dislocations other than shoulder, knee, 
hip) 
0.009 0.007 0.012 
Original Drowning and nonfatal submersion (short or long term, with or without treatment) 0.240 0.197 0.286 
Original Fracture of clavicle, scapula or humerus (short or long term, with or without treatment) 0.038 0.029 0.045 
Modified Fracture of face bone (short or long term with or without treatment) 0.038 0.031 0.044 
Original Fracture of foot bones (short term, with or without treatment) 0.027 0.021 0.033 
Original Fracture of foot bones (long term, without treatment) 0.026 0.019 0.032 
Original Fracture of hand (short term, with or without treatment) 0.010 0.007 0.013 
Original Fracture of hand (long term, without treatment) 0.020 0.015 0.026 
Original Fracture of neck of femur (short term, with or without treatment) 0.228 0.193 0.275 
Original Fracture of neck of femur (long term, with treatment) 0.057 0.045 0.068 
Original Fracture of neck of femur (long term, without treatment) 0.440 0.391 0.493 
Original Fracture of patella, tibia or fibula or ankle (short term, with or without treatment) 0.044 0.034 0.053 
Original Fracture of patella, tibia or fibula or ankle (long term, with or without treatment) 0.051 0.04 0.062 
Original Fracture of pelvis (short term) 0.205 0.171 0.243 
Original Fracture of pelvis (long term) 0.158 0.127 0.194 
Original Fracture of radius or ulna (short term, with or without treatment) 0.030 0.024 0.037 
Original Fracture of radius or ulna (long term, without treatment) 0.052 0.042 0.063 
Original Fracture of skull (short or long term, with or without treatment) 0.083 0.066 0.103 
Original Fracture of sternum and/or fracture of one or two ribs (short term, with or without treatment) 0.185 0.161 0.21 
Original Fracture of vertebral column (short or long term, with or without treatment) 0.101 0.084 0.124 
Original Fracture, other than femoral neck (short term, with or without treatment) 0.080 0.064 0.097 
Original Fracture, other than femoral neck (long term, without treatment) 0.042 0.032 0.051 
Original Fractures, treated (long term) 0.005 0.004 0.008 
Original Injured nerves (short term) 0.126 0.104 0.156 
Original Injured nerves (long term) 0.074 0.059 0.088 
Original Injury to eyes (short term) 0.060 0.048 0.072 
New Concussion 0.104 0.085 0.126 
Original Traumatic brain injury, long-term consequences, minor (with or without treatment) 0.089 0.072 0.109 
Original Traumatic brain injury, long-term consequences, moderate (with or without treatment) 0.214 0.18 0.252 
Original Severe traumatic brain injury, short term (with or without treatment) 0.192 0.151 0.228 
Original Traumatic brain injury, long-term consequences, severe (with or without treatment) 0.604 0.539 0.674 
Original Open wound (short term, with or without treatment) 0.007 0.005 0.01 
Original Poisoning (short term with or without treatment) 0.170 0.139 0.202 
Original Severe chest injury (short term, with or without treatment) 0.377 0.333 0.434 
Original Severe chest injury (long term, with or without treatment) 0.047 0.036 0.056 
Modified Spinal cord lesion below neck level (treated) 0.298 0.256 0.349 
Modified Spinal cord lesion below neck level (untreated) 0.619 0.553 0.696 
Modified Spinal cord lesion at neck level (treated) 0.520 0.465 0.581 
Modified Spinal cord lesion at neck level (untreated) 0.648 0.578 0.728 
 Neurological disorders    
Original Dementia, mild 0.059 0.048 0.073 
Original Dementia, moderate 0.434 0.38 0.481 
New Encephalopathy - moderate 0.410 0.358 0.47 
New Encephalopathy - severe 0.447 0.391 0.501 
New Epilepsy, seizures > = once a month 0.488 0.432 0.546 
New Epilepsy, seizures 1–11 per year 0.255 0.215 0.294 
Original Epilepsy, severe 0.562 0.505 0.631 
Original Epilepsy, treated, with recent seizures 0.335 0.294 0.388 
Original Multiple sclerosis, mild 0.160 0.128 0.195 
Original Multiple sclerosis, moderate 0.469 0.417 0.531 
Original Multiple sclerosis, severe 0.677 0.594 0.757 
Original Parkinson's disease, mild 0.016 0.012 0.022 
Original Parkinson's disease, moderate 0.239 0.205 0.286 
Original Parkinson's disease, severe 0.530 0.477 0.59 
New Trigeminal neuralgia 0.068 0.056 0.084 
New Vertigo and balance disorder (Menière, labyrinthitis) 0.097 0.079 0.119 
 Other    
Original Abdominopelvic problem, mild 0.018 0.013 0.022 
Original Abdominopelvic problem, moderate 0.123 0.1 0.15 
Original Abdominopelvic problem, severe 0.310 0.262 0.355 
New Allergic rhinitis (hay fever) 0.006 0.004 0.009 
New Anal fissure/abscess/fistula 0.082 0.066 0.1 
Original Anemia, mild 0.004 0.003 0.006 
Original Anemia, moderate 0.045 0.035 0.054 
Original Anemia, severe 0.118 0.098 0.145 
New Carpal tunnel syndrome 0.039 0.031 0.047 
Original Conjunctivitis without corneal scar 0.015 0.011 0.019 
Modifed Generic uncomplicated disease: anxiety about diagnosis 0.021 0.015 0.026 
Original Generic uncomplicated disease: worry and daily medication 0.070 0.057 0.088 
New Haemorrhoids 0.109 0.085 0.133 
New Hyperthyroidism 0.144 0.115 0.176 
New Hypothyroidism 0.022 0.017 0.028 
New Insomnia 0.023 0.017 0.028 
New Intensive care unit admission 0.655 0.579 0.727 
New Invasive device/drain 0.163 0.131 0.198 
Original Motor impairment, mild 0.011 0.008 0.014 
Original Motor impairment, moderate 0.053 0.042 0.064 
Original Motor impairment, severe 0.421 0.377 0.477 
Modified Motor plus cognitive impairments, mild 0.044 0.035 0.053 
Modified Motor plus cognitive impairments, moderate 0.185 0.154 0.223 
Modified Motor plus cognitive impairments, severe 0.494 0.438 0.557 
New Sleep apnoea 0.036 0.027 0.044 
New Varicose veins 0.020 0.016 0.025 
1 Original = original GBD 2010 health states [25]; New = new health states; Modified = modified GBD 2010 health states. 
The results show that the disability weights are ranked logically; lowest disability weights 
were attributed to mild health states, such as mild hearing impairment (disability weight 
0.005) and mild acute infectious disease (disability weight 0.007), and highest disability 
weights were attributed to severe health states, such as the terminal phase of cancer or 
chronic kidney disease without medication (disability weight 0.588) and untreated spinal cord 
lesion below neck level (disability weight 0.648). This is illustrated by increasing disability 
weights by level of severity within specific types of diseases. For example, mild diarrhea 
(disability weight 0.073) is rated lower than moderate diarrhea (disability weight 0.149) and 
severe diarrhea (disability weight 0.239). 
Comparison to GBD disability weights 
For 141 (82.0%) of the 172 health states that were included in the European and GBD 
studies, the point estimate of the European disability weight fell within the 95% UI of the 
GBD 2010 disability weights. For 17 (10.1%) health states the European disability weights 
were higher than the upper bound, and for 11 (6.5%) health states the European disability 
weights were lower than the lower bound of the 95% UI from the GBD 2010 study. 
In absolute terms, differences between GBD and European disability weights ranged from 
−0.165 (HIV, cases, symptomatic, pre-AIDS; GBD 2010 disability weight = 0.186, European 
disability weight = 0.351) to 0.185 (fracture of pelvis, short term; GBD 2010 disability 
weight = 0.390, European disability weight = 0.205). The relative difference ranged from 0% 
to 61%, with the highest relative differences generally appearing in cases of low disability 
weights (asthma controlled GBD 2010 disability weight = 0.009, European disability weight 
= 0.015; fractures treated, long term GBD 2010 disability weight = 0.003, European disability 
weight = 0.005). 
Discussion 
This study aimed to assess disability weights for 255 health states. The resulting disability 
weights were ranked logically; the lowest disability weights were attributed to mild health 
states and the highest disability weights to severe health states. Furthermore, the results 
pointed to a high level of overall agreement in paired comparison responses across four 
countries, as indicated by high linear correlations in country-specific results from probit 
regression analyses. 
Strengths of the current study 
Thus far, the largest European disability weights study, published in 2003, included 232 
respondents [33]. Apart from a lower number of health states, different valuation techniques 
and sample size, the study of Schwarzinger et al. utilized a different panel composition, 
namely health professionals rather than a population panel [33]. Since burden of disease 
studies are used primarily as a tool for decision-making on resource allocation at a population 
level, it has been recommended to incorporate the views of the general public to inform 
decision-making in a democratic society [25,28]. However, the majority of previously 
performed disability weight studies asked health professionals to value health states. Studies 
that included both medical experts and members of the general public showed significant 
differences between disability weights derived from these two groups [34-36]. 
Web-based survey 
A limitation of this study is that we used a web-based survey to collect the data. Internet users 
tend to be more highly educated and younger than the general EU population [37]. We have 
tried to mitigate these limitations by using existing large internet panels in the selected 
European countries. By selecting panel members with certain characteristics (in our case, age, 
sex, and educational level) from the existing large panel, the panel of participants for this 
study could be composed in such a way that it was representative of the population aged 18 to 
65 years in the selected countries. Our panel did not include participants older than 65 years. 
For the age groups over age 65 it was too difficult to find enough participants. The GBD 
2010 disability weights study did include respondents aged 65 and older (approximately 5% 
of the total sample). 
Population health equivalence 
Based on responses to population health equivalence questions, as expected, the probability 
of choosing the second health program option was higher with increasing bid (i.e., a higher 
number people that are prevented from getting a certain illness). However, the differences 
between the choice probabilities with the highest (10,000 people prevented from getting a 
certain illness) and lowest bids (1,500 people prevented from getting that illness) were small. 
The relatively small difference is consistent with large numbers of respondents answering 
randomly, which will drive all aggregate-level response probabilities toward 50% and thus 
dilute differences across types of outcomes (either defined by different numbers of 
beneficiaries or different severity of the health state under consideration). The spans in 
response probabilities between the low and high bids were smallest among those with lower 
education. In the GBD study, the PHE was included in the web-based survey as well [25]. 
However, the educational level of the respondents of the GBD study was much higher (93% 
with a higher education) compared to our study (25% with a higher education), and 
respondents to the GBD survey were a self-selected group who were evidently interested 
enough in the content of the survey to participate voluntarily. This may have resulted in 
greater attention to the question and care in weighing the responses, both of which are likely 
to have improved the signal-to-noise ratio in the responses. We conclude from the results in 
the present study that the discrete choice formulation of the PHE may not be suitable for use 
in a general population survey administered by the internet. 
Disability weights 
The ranking of certain conditions seems counterintuitive. For instance, the disability weight 
for profound intellectual disability is lower than the disability weight for back pain. A 
possible explanation for this may be that brief lay descriptions were used to describe the 
major functional consequences and symptoms associated with the health state and that the 
disease label, indicating the cause of the health state, was removed from the description. The 
latter was a deliberate choice, because the disease label may elicit bias for stigmatizing 
conditions [25]. However, previous studies showed that including certain disease information 
in health state descriptions yields different values [38]. A second explanation may be the 
framing of the paired comparison. In the pairwise comparison respondents are asked to judge 
the level of health of the health states, and this may lead to bias if respondents consider some 
health states as not being associated with “being ill” [26]. 
For future health state valuation studies that use a similar design and a similar panel 
composition it is important to consider different techniques to anchor estimates from paired 
comparisons onto the disability weight scale, such as the time trade-off or the standard 
gamble. However, each of these existing techniques to measure health state preferences 
suffers from limitations that hamper their application in a study design where a web-based 
survey is used to collect health state valuations from a panel that consists of members of the 
general public. Alternatively, the disability weights may be recalibrated post-hoc by health 
professionals. Health professionals are argued to have the ability to make careful comparative 
judgments. However, an argument against the use of a panel composed of health 
professionals is that the disability weights will not entirely reflect the views of the global 
population, as has been recommended. 
Agreement between European disability weights and GBD 2010 disability 
weights 
Given the lack of feasibility of the discrete choice PHE in this sample, an alternative 
rescaling procedure was applied based on non-parametric regression. It is important to note 
that as a result, this study does not include new information on tradeoffs between nonfatal 
and fatal outcomes, which are central to the rescaling of results to a unique 0-to-1 disability 
weights scale. We therefore emphasize that comparison of disability weights between this 
study and GBD 2010 should be understood as reflecting variation in comparative evaluations 
of different functional outcomes (as manifest in responses to paired comparison questions) 
rather than a complete assessment of differences in the valuation of nonfatal versus fatal 
health outcomes. 
Cultural differences 
Similar to the GBD 2010 disability weights measurement study, our study aspired to quantify 
health loss as opposed to welfare loss [25]. Previous studies have shown that there are clear 
cultural differences in the ways people perceive health problems and how such problems 
affect their lives [39-43]. This was endorsed by Üstün et al., who found significant 
differences in ranking of health states between 14 countries [36]. Furthermore, the findings 
from Jelsma et al. suggest that the effect of cultural differences on health state valuations may 
be stronger among lay people compared to health professionals [35]. However, in the largest 
disability weights study thus far, Salomon et al. found that comparative paired comparisons 
of different functional outcomes produced similar results in samples that varied with respect 
to cultural, educational, environmental, and demographic circumstances [25]. The current 
study also found a high degree of consistency between countries, though it should be noted 
that all of the countries in our study were high-income European settings, so we caution 
against over-generalization of the significance of the findings. Apart from cultural 
differences, other differences between high- and low-income settings may also influence how 
people weigh different health outcomes. For example, we might hypothesize that diseases and 
injuries rated as less severe by experts in a high-income country could be rated as more 
burdensome by people in low-income settings. Further research is needed to gain greater 
insight into the effects of cultural differences on disability weights, particularly in low-
income settings. 
Conclusions 
Limitations notwithstanding, this study provided an opportunity to expand the evidence base 
on disability weights derived from the GBD disability weights measurement study, since PC 
assessments of health outcomes in this study resulted in estimates that were highly correlated 
across four European countries. Furthermore, the European disability weights study provided 
the opportunity to expand the set of health outcomes that will be covered in the burden of 
communicable disease study in the European Union/EEA/EFTA countries and the next 
revision of the GBD. 
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